vTv Therapeutics (VTVT) Q3 2024 earnings summary

Executive summary

• Lead program cadisegliatin is being developed as an oral adjunct therapy for type 1 diabetes, with ongoing efforts to address an FDA clinical hold placed in July 2024; additional in vitro studies are required before trials can resume.

• No product revenue to date; revenue is derived from milestone and license payments under collaboration agreements.

• Recent private placement and ATM offering raised $53.5 million to support ongoing R&D and clinical activities, significantly strengthening the cash position.

Financial highlights

• Net loss attributable to common shareholders was $4.8 million ($0.88 per share) for Q3 2024, an improvement from $6.7 million ($3.19 per share) in Q3 2023.

• For the nine months ended September 30, 2024, net loss was $14.8 million, down from $16.8 million in the prior year period.

• Revenue of $1.0 million recognized in the nine months ended September 30, 2024, due to a milestone under the Newsoara License Agreement; no revenue in Q3 2024.

• Cash and cash equivalents totaled $41.6 million as of September 30, 2024, up from $9.4 million at December 31, 2023, mainly due to financing activities.

• Other income for Q3 2024 was $0.2 million, mainly from gains related to warrant fair value changes; Q3 2023 saw a $3.3 million expense due to an impairment charge.

Outlook and guidance

• Current cash position expected to fund operations for at least the next twelve months.

• Ongoing discussions with the FDA regarding the clinical hold on cadisegliatin are expected to continue, with plans to resume trials and target international registrational studies for 2026.

• Additional capital may be required for future clinical and commercialization activities.

• The company is focused on advancing its clinical pipeline, particularly cadisegliatin for type 1 diabetes and exploring additional indications.